Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation (COMPRIGEL)

February 1, 2018 updated by: Biose

Study Evaluating the Optimal Dosage for Equivalence Between a Tablet and Capsule Dosage Form of an Intravaginal Treatment With Total Freeze-dried Culture of Lcr Regenerans® (Lactobacillus Rhamnosus Lcr35®) on Vaginal Flora Colonisation in Healthy Women.

The primary objective of this study is to study the vaginal flora colonisation equivalence between the tablet and capsule dosage forms of a treatment with Lcr Regenerans® between D0 (V1) and Dend of treatment.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The healthy vaginal microbiota is mainly colonised by strains of Lactobacillus which play an important role in defence against vaginal infections. The intravaginal use of probiotic strains stimulating the recolonisation of the endogenous vaginal microbiota and capable of inhibiting the growth of pathogens such as Candida albicans appears to be an interesting alternative to prevent recurrences of VVC. Recently, longitudinal studies have revealed that the vaginal microbiota is relatively stable and that the main cause of disturbance to the stability of the vaginal microbiota is over short menstruation periods. However, the use of antimicrobial agents induces severe disturbances with disappearance of certain endogenous species over several weeks. These results suggest that antimicrobial treatments severely affect the vaginal flora and that probiotics are therefore recommended to help re-establish a vaginal microbiota after this treatment.

For this, a sufficient direct local supply must be provided. The general data from studying the vaginal microbiota reveal that in the healthy woman, the concentration of Lactobacilli is greater than or equal to 107 CFU/ml of vaginal secretion. During capsule administration, all the Lactobacilli are immediately released into the vaginal cavity. The natural vaginal secretions, estimated to be an average of 0.51 ml/day, result in daily elimination of around 107 to 108 CFU and therefore generates very rapid elimination of this supply which requires daily administrations.

The objective of this clinical trial is to prove that the two dosage forms, capsule administered daily and tablet administered at a certain dosage, enable equivalent local provision of a concentration which is greater than or equal to 10e7 CFU (this concentration ensures the establishment of a sufficiently large bacterial population to enable efficacy of the product).

Therefore, the optimal dosage of the Lcr Regenerans® tablet to be administered and which will be equivalent to the daily administration of the Lcr Regenerans® capsule will be determined during this trial. To do this, 3 different dosages of the Lcr Regenerans® tablet, corresponding to or encompassing the time during which the tablet provides continuous release and presence of the strain in the in vitro model, will be compared to that of the Lcr Regenerans® capsule. For this reason, the frequencies of administration for the Lcr Regenerans® tablet will be 3, 4 or 5 days.

Study Type

Interventional

Enrollment (Actual)

34

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Aurillac, France, 15000
        • BIOSE

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

Relating to the condition:

  • Clinically healthy women

Relating to the population:

  • Adult women
  • Women of child-bearing age: with a negative urine pregnancy test and using a method of contraception deemed effective by the investigator(excluding spermicides) throughout the trial
  • Women who can be treated with the study product immediately after the inclusion visit for a duration of 21 consecutive days without interruption by her next menstrual period.
  • Women who can speak and read French and having been informed about the study and having voluntarily signed an Informed Consent Form
  • Women registered with a social insurance scheme

Exclusion Criteria:

  • Relating to the condition or the gynaecological field:
  • Presence of a presumed or proven gynaecological bacterial or viral infection, whether treated or not during the month preceding inclusion.
  • Presence of an existing gynaecological condition that could interfere with the assessment of the trial treatment (severe cervical dysplasia or carcinoma in situ, invasive carcinoma, intra-epithelial cervical neoplasia, squamous intra-epithelial lesions etc.)

Relating to the treatments:

  • Systemic antifungals or antibiotics during the month preceding the inclusion visit.
  • Use of probiotics (see list in 16.2) during the month preceding the inclusion visit.
  • Use of prebiotics (acidifying agents) - (see list in 16.2) during the 15 days preceding the inclusion visit.
  • Allergy to one of the active ingredients or one of the excipients in the products.

Relating to the population:

  • Women unable to comply with the constraints of the protocol.
  • Breastfeeding women.
  • Post-menopausal women.
  • Women whose menstrual bleeding lasts longer than 8 days per month.
  • Women having participated in a clinical study in the 3 months preceding inclusion in this protocol.
  • Women with a severe acute or chronic condition deemed by the investigator as being incompatible with participation in the trial or a serious infection which could be life-threatening in the short term.
  • Immunosuppressed women.
  • Women with a previous condition which, according to the investigator, is likely to interfere with the study results or expose the female volunteer to additional risk.
  • Women with linguistic (not speaking or writing French) or psychological inability to understand and sign the informed consent form.
  • Women deprived of her liberty through an administrative or judicial decision or subject to a guardianship order.
  • Women likely not to comply with the treatment.
  • Women who cannot be contacted in the case of emergency.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Lcr Regenerans® vaginal capsule
Name: Lcr Regenerans® containing at least 10e7 CFU per intravaginal capsule. 1 vaginal capsule per day
Device: Lcr Regenerans® vaginal capsules
Other Names:
  • GYNOPHILUS Capsules
Experimental: Lcr Regenerans® vaginal tablet every 3 days
Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 3 days
Device: Lcr Regenerans® vaginal tablet
Other Names:
  • GYNOPHILUS Tablet
Experimental: Lcr Regenerans® vaginal tablet every 4 days
Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 4 days
Device: Lcr Regenerans® vaginal tablet
Other Names:
  • GYNOPHILUS Tablet
Experimental: Lcr Regenerans® vaginal tablet every 5 days
Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 5 days
Device: Lcr Regenerans® vaginal tablet
Other Names:
  • GYNOPHILUS Tablet

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Measure the vaginal flora equivalence between the tablet and the capsule dosage forms of a treatment with Lcr Regenerans® between D0 (V1) and Dend of treatment.
Time Frame: 21 days
21 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Biose

Investigators

  • Principal Investigator: Yann Dr LENGLET, Hospital center Jacques LACARIN of VICHY

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2015

Primary Completion (Actual)

January 1, 2016

Study Completion (Actual)

January 1, 2018

Study Registration Dates

First Submitted

April 1, 2016

First Submitted That Met QC Criteria

April 5, 2016

First Posted (Estimate)

April 6, 2016

Study Record Updates

Last Update Posted (Actual)

February 5, 2018

Last Update Submitted That Met QC Criteria

February 1, 2018

Last Verified

February 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PRO_2014-01
  • 2014-001746-21 (EudraCT Number)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Candidiasis, Vulvovaginal

Clinical Trials on Lcr Regenerans® vaginal capsules

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe